Portal de Periódicos da CAPES

Artigo Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

Neurological and cognitive impairment in COVID‐19: clinical characterization andepidemiological

2023; Wiley; Volume: 19; Issue: S4 Linguagem: Inglês

10.1002/alz.059664

1552-5279

José Wagner Leonel Tavares-Júnior, Pedro Braga‐Neto, Manoel Alves Sobreira-Neto, Raquel Carvalho Montenegro, CAROLINE DE FÁTIMA AQUINO MOREIRA, Laís Lacerda Brasil de Oliveira, Jean Breno Silveira da Silva, Carmem Meyve Pereira Gomes, Safira de Brito Gaspar, Letícia Chaves Vieira Cunha, Artur Victor Menezes Sousa, Werbety Lucas Queiroz Feitosa, Danilo Nunes Oliveira,

COVID-19 Clinical Research Studies

Abstract Background COVID‐19 neurological manifestations were demonstrated during the pandemic, including cognitive impairment. Objectives: To determine the prevalence of cognitive and behavioral complaints (such as dementia, MCI or SCD) in a outpatient sample with recent SARS‐COV2 infection. Specific: Evaluate the association of cognitive impairment with the presence of the polymorphism found in the APOE gene and with respiratory disease Method Observational, longitudinal, prospective clinical study. Inclusion criteria: patients with confirmed Covid‐19. Patients are evaluated in an outpatient clinic. They are evaluated through a standardized attendance record, with somatic and cognitive neurological assessment. Cognitive assessment involves the application of cognitive (ACER, MMSE and CDR), functional (Pfeffer) and psychiatric (GDS or Beck) screening instruments, in addition to subsequent extensive neuropsychological assessment. In addition, APOE polymorphism is analysed. Results To date, 200 patients were evaluated. The average age is 46.5 years, with 65.4% female, 79.16% with 8 or more years of schooling, in addition to 57.5% of the sample with cognitive complaints. Conclusions The results so far in our study demonstrate that cognitive complaints are frequent in patients even in the chronic phase of the disease.